Indefinite Delivery Contract HHSN272201100021I
Award Date
8/29/11
Last Date to Order
9/28/28
Federal Agency
National Institute of Allergy and Infectious Diseases
Ultimate Awardee
Not listed
NAICS Category
541712 - Research and Development in the Physical, Engineering, and Life Sciences (except Biotechnology)
Federal Contract Vehicle
Pricing Type
Order Dependent (IDV only)
Legislative Mandate
Not listed
National Interest Action
None
Award Type
Single
Primary Consortia Member
Not listed
Similar IDVs
This is a single-award Indefinite Delivery Contract issued by the National Institutes of Health's National Institute of Allergy and Infectious Diseases (NIAID) to Advanced Bioscience Laboratories, Inc. (ABL), a foreign-owned for-profit organization that manufactures biologics. The Diagnostics Pre-Clinical Services Program IDIQ contract has a potential value of $24,000,000 over a 7-year ordering period ending June 2030. Under this contract, ABL will provide a broad range of preclinical diagnostic...
This Indefinite Delivery Contract (IDC) was awarded by the National Institute of Allergy and Infectious Diseases (NIAID), a component of the National Institutes of Health (NIH), to Advanced Bioscience Laboratories, Inc. (ABL), a leading contract research and manufacturing organization. The $80 million IDC is for manufacturing and characterization services for vaccines and other biologics targeting infectious diseases. Under this IDC, ABL has been issued multiple task orders for a range of...
The provided information describes an Indefinite Delivery Contract (IDC) awarded by the National Center for Advancing Translational Sciences (NCATS), a civilian agency of the U.S. government. The contract was awarded to Advanced Bioscience Laboratories, Inc. (ABL), a foreign-owned, for-profit manufacturer of goods specializing in biopharmaceutical research and development. The IDC, valued at a ceiling of $48,882,666, covers a broad range of pharmacology studies, animal model development, and...
The key products and services being delivered under this federal contract IDV award are to support preclinical development efforts for the National Institute of Allergy and Infectious Diseases (NIAID), a component of the U.S. Department of Health and Human Services. The prime contractor, Advanced Bioscience Laboratories, Inc. (ABL), a foreign-owned, for-profit manufacturer of goods, has been awarded multiple delivery orders under this IDV to provide a range of services including cGMP...
This federal contract indefinite delivery vehicle (IDV) was awarded by the National Institute of Allergy and Infectious Diseases (NIAID), a civilian agency within the U.S. Department of Health and Human Services, to Advanced Bioscience Laboratories, Inc. (ABL), a foreign-owned, for-profit manufacturer of goods. The $98.9 million IDV, titled "Resources to Advance Pediatrics and HIV Prevention Science", covers a range of preclinical development support services including cGMP...
This Indefinite Delivery Contract (IDC) was awarded by the National Center for Advancing Translational Sciences (NCATS), a civilian agency under the National Institutes of Health (NIH), to Advanced Bioscience Laboratories, Inc. (ABL). The $49.9 million, multiple-award IDC will provide Chemistry, Manufacturing, and Control (CMC) and related services to support the development of drug products from August 2024 through July 2031. The contract aims to obtain a broad range of preclinical services...
This is an Indefinite Delivery Contract (IDC) awarded by the Department of Health and Human Services' National Institutes of Health (NIH) National Center for Advancing Translational Sciences (NCATS) to Advanced Bioscience Laboratories, Inc. (ABL) for Chemistry, Manufacturing and Controls (CMC) and related services to support the development of drug substances. The contract has a potential value of $49,713,679 and a period of performance from May 15, 2024 to May 14, 2031. It is a multiple award...
This indefinite delivery contract was awarded by the National Cancer Institute (NCI), part of the National Institutes of Health (NIH) under the Department of Health and Human Services (HHS). The contract, valued at up to $74,995,000, is a multiple award with Advanced Bioscience Laboratories, Inc. (ABL) as the prime contractor. The contract supports the PREVENT Cancer Preclinical Drug Development Program, with the objective of cGMP production of vaccines and biologicals for cancer prevention. Key...
The National Institute of Allergy and Infectious Diseases (NIAID), a civilian agency of the U.S. Department of Health and Human Services, has awarded an Indefinite Delivery/Indefinite Quantity (IDIQ) contract worth up to $107,274,471 to provide preclinical development support for candidate products and drug development activities related to HIV, hepatitis B and C, and tuberculosis. This multiple-award IDIQ contract has a 7-year period of performance from October 2020 to October 2027. The scope...
This indefinite delivery contract (IDC) was awarded by the National Institute of Allergy and Infectious Diseases (NIAID), a civilian agency within the Department of Health and Human Services, to the American Foundation For Biological Research, doing business as the Biomedical Research Institute. The $146.3 million single-award IDC has a period of performance from July 15, 2024 to July 14, 2031. The purpose of this IDC is to provide NIAID with the capability and capacity to develop and employ...